Key Highlights

  • Wellnex Life has agreed to sell Pain Away to Mentholatum Australasia for up to AUD 21.3mn in cash.
  • The consideration comprises AUD 19.8mn payable at completion and a potential AUD 1.5mn earn-out.
  • Wellnex plans to repay approximately AUD 10.2mn of secured and unsecured borrowings at completion.
  • Shareholders are scheduled to vote on the transaction on 8 September 2026.

Wellnex Life Limited (ASX/AIM:WNX) is preparing for a major reshaping of its business after signing a binding agreement to sell Pain Away to Mentholatum Australasia. The proposed transaction values the brand and related assets at up to AUD 21.3mn in cash.

The sale would convert Wellnex’s flagship asset into funds for debt repayment, working capital and future growth. It would also leave the company reliant on a smaller portfolio of retained consumer-healthcare products and contract manufacturing, making post-sale execution central to the investment case.

Company Overview

Wellnex Life operates in consumer healthcare, branded products and contract manufacturing. Pain Away has been an important contributor to the group, while the remaining business includes liquid soft-gel analgesics supported by Wellnex’s own Therapeutic Goods Administration marketing authorisations.

The company also works with global partners through a capital-light contract-manufacturing model. Following the proposed disposal, the board intends to focus on sustainable profitability, positive free cash flow and selective opportunities in established consumer brands.

Transaction Structure

Mentholatum Australasia has agreed to pay AUD 19.8mn at completion, subject to customary adjustments. A further earn-out of up to AUD 1.5mn is linked to the Pain Away business achieving threshold and target normalised EBITDA during the 12 months after completion.

An aggregate AUD 1mn of the completion payment will be held in escrow. Portions will cover post-completion adjustments, raw-material stability testing and potential claims relating to Pain Away intellectual property and brand protection.

The sale covers intellectual property, inventory, goodwill and other assets used in operating Pain Away. Wellnex will face a five-year restraint on competing with the business in Australia and New Zealand.

Why Wellnex Chose a Cash Sale

Wellnex disclosed unsolicited preliminary acquisition interest in February 2026 and had also considered convertible-note funding to support international expansion. After reviewing the alternatives, the board selected a cash sale.

Pain Away generated approximately AUD 13.38mn of unaudited revenue and AUD 4.36mn of unaudited EBITDA in FY25. Its unaudited gross assets stood at AUD 22.76mn at 31 December 2025.

The transaction therefore removes a meaningful earnings contributor. In exchange, Wellnex gains the ability to reduce financial pressure and redirect capital towards the remaining operations.

Debt Repayment Resets the Balance Sheet

Wellnex intends to repay approximately AUD 10.2mn of secured and unsecured borrowings, including interest. That amount includes loans to former directors whose repayment date has been extended to transaction completion without additional cost.

Remaining funds may support working capital, settle trade and operating liabilities, scale existing operations, fund disciplined consumer-brand opportunities or contribute to a potential capital return. The board will determine the allocation after completion.

Shareholder Approval and Completion

The transaction requires shareholder approval under AIM Rule 15 because of Pain Away’s size relative to Wellnex. A general meeting is scheduled for 8 September 2026.

The ASX has provided in-principle advice that approval is not required under rules covering a significant change in business scale or disposal of a main undertaking. Completion is expected shortly after shareholder approval and satisfaction of other conditions. The agreement has a 30 October 2026 sunset date unless extended.

What May Shape the Next Move

The shareholder vote is the immediate event. If approved, attention will shift to completion, debt repayment, the final escrow position and whether the earn-out becomes payable.

Beyond the transaction, Wellnex must demonstrate that its retained soft-gel and contract-manufacturing operations can scale towards profitability and positive free cash flow without Pain Away.

Risks

  • Shareholders may not approve the transaction or conditions may not be satisfied.
  • The earn-out depends on Pain Away’s post-completion EBITDA performance.
  • The sale removes a business that contributed material revenue and EBITDA.
  • The remaining operations may take time to reach sustainable profitability.
  • Working-capital requirements may reduce funds available for growth or a capital return.